Fwd: Identifying symptoms of ovarian cancer: a qualitative and quantitative study.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Identifying symptoms of ovarian cancer: a qualitative and quantitative study.
To: mesothelioma77@gmail.com


[1]BJOG. 2008 Jul; 115(8): 1008-14
Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, Mant D, Kehoe ST, Austoker J

INTRODUCTION: Symptoms of ovarian cancer are often vague and consequently a high proportion of women with ovarian cancer are not referred to the appropriate clinic. OBJECTIVE: To identify diagnostic factors for ovarian cancer. DESIGN: A qualitative and quantitative study. SETTING: Four UK hospitals. SAMPLE: One hundred and twenty-four women referred to hospital with suspected ovarian malignancy. METHODS: Women were interviewed prior to diagnosis (n = 63), or soon after. A thematic analysis was conducted. Emergent symptoms were quantitatively analysed to identify distinguishing features of ovarian cancer. MAIN OUTCOMES: Symptoms in women with and without ovarian cancer. RESULTS: Diagnoses comprised 44 malignancies, 59 benign gynaecological pathologies and 21 normal findings. Of the malignancies, 25 women had stage III or more disease, with an average age of 59 years. The benign/normal cohort was significantly younger (48 years). Multivariate analysis revealed persistent abdominal distension (OR 5.2, 95% CI 1.3-20.5), postmenopausal bleeding (OR 9.2, 95% CI 1.1-76.1), appetite loss (OR 3.2, 95% CI 1.1-9.2), early satiety (OR 5.0, 95% CI 1.6-15.7) and progressive symptoms (OR 3.6, 95% CI 1.3-9.8) as independent, statistically significant variables associated with ovarian cancer. Fluctuating distension was not associated with ovarian cancer (OR 0.4, 95% CI 0-4.1). Women frequently used the term bloating, but this represented two distinct events: persistent abdominal distension and fluctuating distension/discomfort. CONCLUSIONS: Ovarian cancer is not a silent killer. Clinicians should distinguish between persistent and fluctuating distension. Recognition of the significance of symptoms described by women could lead to earlier and more appropriate referral.



___
Source: http://www.hubmed.org/display.cgi?uids=18651882
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Head of Pittsburgh cancer centre urges staff to limit mobile phone use due to risk of disease (Guardian Unlimited)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Head of Pittsburgh cancer centre urges staff to limit mobile phone use due to risk of disease (Guardian Unlimited)
To: mesothelioma77@gmail.com


Head of a leading US research institute reignites controversy over the health risks of using mobile phones

Thu, 24 Jul 2008 20:51:23 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=131na5j27/*http%3A//www.guardian.co.uk/technology/2008/jul/24/mobilephones.cancer?gusrc=rss&feed=worldnews
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.
To: mesothelioma77@gmail.com


[1]BMC Cancer. 2008 Jul 23; 8(1): 205
Xiaorong L, Wei W, Liyuan Q, Kaiyan Y

ABSTRACT: BACKGROUND: DLC2, a unique RhoGAP, has been recently identified as a tumor suppressor gene in hepatocellular carcinoma (HCC). However, the expression of DLC2 protein, and its relationship with RhoA in clinical hepatocellular carcinoma have not been studied. The aim of this study was to investigate the DLC2 protein expression and its correlation with expression of RhoA, as well as to evaluate the prognostic value of DLC2 for HCC patients. METHODS: Western blot and immunohistochemical staining were employed to detect DLC2 protein expression in 128 HCC specimens. The correlation between DLC2 protein expression and clinicopathologic outcome, and prognostic value of DLC2 for HCC patients were analyzed. RESULTS: HCC tissues revealed significantly lower level of DLC2 protein than pericarcinomatous liver tissues (PCLT). There was significant correlation between underexpression of DLC2 protein and cell differentiation. Meanwhile, underexpression of DLC2 protein was correlated with overexression of RhoA. Furthermore, HCC Patients with DLC2-negative expression showed a significantly poorer prognosis than those with DLC2-positve expression. CONCLUSIONS: Our data strongly suggested that decreased DLC2 expression in HCC correlates with cell differentiation of HCC and overexpression of RhoA, underexpression of DLC2 is associated with poor prognosis in HCC patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18651974
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Evaluation of the addition of video-based education for patients receiving standard pre-chemotherapy education.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Evaluation of the addition of video-based education for patients receiving standard pre-chemotherapy education.
To: mesothelioma77@gmail.com


[1]Eur J Cancer Care (Engl). 2008 Jul; 17(4): 328-39
Kinnane N, Thompson L

Preparing cancer patients and their families for chemotherapy treatment is difficult. The challenge lies in finding ways to promote self-care and improve their ability to recall instructions. The aim of this study was to evaluate the usefulness of an educational video with regard to patients' ability to recall and report side effects of treatment. Patients referred for adjuvant chemotherapy for breast and colorectal cancer were randomized to receive standard pre-chemotherapy education or standard education plus addition of a video. Patients completed a base line questionnaire assessing existing knowledge and another questionnaire prior to the second chemotherapy cycle evaluating recall of information. Patients who watched the video were asked to assess the video after six cycles of chemotherapy. Telephone calls to the department reporting symptoms were monitored for both groups. The video group demonstrated trends towards higher recall in information concerning fever, mouth problems, low red cell count and prevention of constipation. They more commonly telephoned reporting medical problems of nausea, vomiting and signs of infection compared with the standard group. In summary, our study demonstrated inclusion of video to standard chemotherapy education improves retention of information regarding management of predictable chemotherapy side effects and reporting of treatment-related symptoms.



___
Source: http://www.hubmed.org/display.cgi?uids=18652000
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prospective study of combined treatment with interferon-alpha and active vitamin D for Japanese patients with metastatic renal cell carcinoma.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Prospective study of combined treatment with interferon-alpha and active vitamin D for Japanese patients with metastatic renal cell carcinoma.
To: mesothelioma77@gmail.com


[1]Int J Urol. 2008 Jul 21;
Obara W, Mizutani Y, Oyama C, Akaza H, Ishii N, Kohri K, Namiki M, Okuyama A, Shima H, Yokoyama M, Shuin T, Miki T, Watanabe Y, Fujioka T

Objectives: To assess the safety and efficacy of combined therapy with interferon-alpha (INF-alpha) and active vitamin D(3) for metastatic renal cell carcinoma (RCC). Methods: Sixteen patients with metastatic RCC were enrolled in this prospective study. All received oral alfacalcidol (1 microg once daily) and INF-alpha (Sumiferon; 3 million units, three times a week). The primary endpoint was the response rate (defined as complete + partial remission). Secondary endpoints were cancer-specific survival and toxicity. The median follow-up period was 17 months (range: 5-49 months). Results: The median age of the patients was 68 years (range: 41-73 years). The sites of metastases were: lung in 13 patients, bone in one, lung and bone in one, and lung, bone, and lymph nodes in one. Four patients (25%) had a partial response (PR), 10 patients (62.5%) showed no change (NC), and two patients (12.5%) had progressive disease (PD). The median cancer-specific survival time was 45 months. One patient had to discontinue vitamin D(3) because of hypercalcemia. Kaplan-Meier survival analysis revealed that metastasis at the time of initial diagnosis and older than average age were significant predictors of poor survival (P

___
Source: http://www.hubmed.org/display.cgi?uids=18651865
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Discovery of 2-Chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a Potent Inducer of Apoptosis with High In Vivo Activity.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Discovery of 2-Chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a Potent Inducer of Apoptosis with High In Vivo Activity.
To: mesothelioma77@gmail.com


[1]J Med Chem. 2008 Jul 24;
Sirisoma N, Kasibhatla S, Pervin A, Zhang H, Jiang S, Willardsen JA, Anderson MB, Baichwal V, Mather GG, Jessing K, Hussain R, Hoang K, Pleiman CM, Tseng B, Drewe J, Cai SX

Using a live cell, high-throughput caspase-3 activator assay, we have identified a novel series of 4-anilinoquinazolines as inducers of apoptosis. In this report, we discuss the discovery of 2-chloro- N-(4-methoxyphenyl)- N-methylquinazolin-4-amine, compound 2b (EP128265, MPI-0441138) as a highly active inducer of apoptosis (EC 50 for caspase activation of 2 nM) and as a potent inhibitor of cell proliferation (GI 50 of 2 nM) in T47D cells. Compound 2b inhibited tubulin polymerization, was effective in cells overexpressing ABC transporter Pgp-1, and was efficacious in the MX-1 human breast and PC-3 prostate cancer mouse models. In contrast to the SAR of 4-anilinoquinazolines as EGFR kinase inhibitors, the methyl group on the nitrogen linker was essential for the apoptosis-inducing activity of 4-anilinoquinazolines and substitution in the 6- and 7-positions of the quinazoline core structure decreased potency.



___
Source: http://www.hubmed.org/display.cgi?uids=18651728
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jul 24;
Llanes-Fernández L, Del Carmen Arango-Prado M, Alcocer-González JM, Guerra-Yi ME, Franco-Odio S, Camacho-Rodríguez R, Madrid-Marina V, Tamez-Guerra R, Rodríguez-Padilla C

Breast cancer patients may express abnormal cellular immune responses affecting their immunological competence. The analysis of immunological parameters may be useful as indicators of T cell function. To determine the expression of lymphocyte activation proteins and cytokines in tumor and non-metastatic axillary lymph nodes, 30 breast cancer patients were monitored. CD3 polypeptides, PTKs (protein tyrosine kinases) and phosphorylated tyrosines were studied by Western Blot and cytokines mRNA expression was determined by RT-PCR (reverse transcription-polymerase chain reaction). This group of patient had shown high immunohistochemistry expression of IL-10 in tumors. Activation proteins were mainly expressed in involved lymph nodes comparing with their expression in tumors. The differences in expression of CD3 polypeptides and p56(lck) between both locations were significant. There was no statistical association between PTKs and IL-10 in the tumor but more than 50% of cases who express IL-10 lost p56(lck), p59(fyn). A direct association between IL-10 and CD3-polypeptides was observed, however 52.2% of patients who express IL-10 did not express 41 kDa CD3-zeta form. IL-10 mRNA was detected in more than 50% of tumors contrary to the prevalence of type 1 cytokines in regional nodes (40%). The lack of expression of lymphocyte activations proteins and the high expression of IL-10 suggest a downregulation on T cells function in the tumors. These results are useful in order to understand the local immune response that would be key in the control of the tumor progression.



___
Source: http://www.hubmed.org/display.cgi?uids=18651178
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Expectoration of a lung metastasis in a patient with colorectal carcinoma.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jul 25, 2008 at 11:44 PM
Subject: Expectoration of a lung metastasis in a patient with colorectal carcinoma.
To: mesothelioma77@gmail.com


[1]Clin Colorectal Cancer. 2008 Jul; 7(4): 283-6
Ghetie C, Davies M, Cornfeld D, Suh N, Saif MW

Metastatic disease is present in up to 20% of patients at the time of diagnosis of colorectal cancer. The most frequently involved sites are the liver and the lungs. A rare form of lung metastatic disease is endobronchial metastases, most commonly seen with breast cancer and colon cancer. Their clinical and imaging profile is similar to primary bronchogenic carcinoma. Tumor expectoration is an unusual manifestation of endobronchial metastases (as well as of the primary lung carcinoma). We report the case of a 75-year-old man with known liver and lung metastatic disease from colon cancer who experienced an episode of tissue expectoration. Pathology examination of the expectorated piece of tissue was consistent with colonic adenocarcinoma. Tumor expectoration is a rare event, with

___
Source: http://www.hubmed.org/display.cgi?uids=18650198
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:29 AM
Subject: Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jul 21;
Perez D, Herrmann T, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N, Clavien PA, Marino S, Seifert B, Jaeger D

Cancer testis antigens (CTAs) are expressed in a variety of malignant tumors but not in any normal adult tissues except germ cells and occasionally placenta. Because of this tumor-associated pattern of expression, CTAs are regarded as potential vaccine targets. The expression of CTAs in gastrointestinal stromal tumors (GIST) has not been analyzed systematically previously. The present study was performed to analyze the expression of CTA in GIST and to determine if CTA expression correlates with prognosis. Thirty-five GIST patients were retrospectively analyzed for their expression of CTAs by immunohistochemistry using the followingmonoclonal antibodies (mAb/antigen): MA454/MAGE-A1, M3H67/MAGE-A3, 57B/MAGE-A4, CT7-33/MAGE-C1 and E978/NY-ESO-1. Fourteen tumors (40%) expressed 1 or more of the 5 CTAs tested. Fourteen percent (n = 5/35) were positive for MAGE-A1, MAGE-A3 or MAGE-A4, respectively. Twenty-six percent (n = 9/35) stained positive for MAGE-C1 and 20% (n = 7/35) for NY-ESO-1. A highly significant correlation between CTA expression and tumor recurrence risk was observed (71% vs. 29%; p = 0.027). In our study population, the high-risk GIST expressed CTAs more frequently than low-risk GIST (p = 0.012). High-risk GISTs which stained positive for at least 1 CTA, recurred in 100% (n = 25) of the cases. This is the first study analyzing CTA expression in GIST and its prognostic value for recurrence. The CTA staining could add information to the individual patient prognosis and represent an interesting target for future treatment strategies. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18646188
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Receipt of standard breast cancer treatment by african american and white women.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Receipt of standard breast cancer treatment by african american and white women.
To: mesothelioma77@gmail.com


[1]Int J Med Sci. 2008; 5(4): 181-8
Worthington J, Waterbor JW, Funkhouser E, Falkson C, Cofield S, Fouad M

Objectives: Breast cancer mortality is higher among African Americans than for Whites, though their breast cancer incidence is lower. This study examines whether this disparity may be due to differential receipt of treatment defined as "standard of care" or "addition to standard of care" by the National Comprehensive Cancer Network (NCCN).Design: Incident, female breast cancer cases, 2,203 African American and 7,518 White, diagnosed during 1996-2002 were identified from the Alabama Statewide Cancer Registry. Breast cancer treatment was characterized as whether or not a woman received standard of care as defined by the NCCN. For cases characterized as receiving standard of care, addition to standard of care was also evaluated, defined as receiving at least one additional treatment modality according to NCCN guidelines. Logistic models were used to evaluate racial differences in standard and addition to standard of care and to adjust for age, stage at diagnosis, year of diagnosis and area of residence.Results: No racial differences were found for standard (Prevalence Ratio (PR)=1.00) or for addition to standard of care (PR=1.00) after adjustment for confounders. When the adjusted models were examined separately by age, stage, and area of residence, overall no racial differences were found.Conclusion: No racial differences in standard of care and addition to standard of care for breast cancer treatment were found. Therefore, both African Americans and Whites received comparable treatment according to NCCN guidelines.



___
Source: http://www.hubmed.org/display.cgi?uids=18645609
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Associations between serum testosterone levels, cell proliferation and progesterone receptor content in normal and malignant breast tissue in postmenopausal women.
To: mesothelioma77@gmail.com


[1]Gynecol Endocrinol. 2008 Jul; 24(7): 405-10
Hofling M, Lofgren L, von Schoultz E, Carlstrom K, Soderqvist G

Progestogens and progesterone receptors (PR) may play an important role in increased breast proliferation following combined estrogen/progestogen hormone therapy, while androgens may counteract this effect. In 50 untreated healthy postmenopausal women and 48 untreated postmenopausal breast cancer patients, we measured serum levels of testosterone (T), sex hormone-binding globulin (SHBG), estrone (E(1)) and adrenal androgens; and additionally, in the breast cancer patients, cortisol and corticosteroid-binding globulin and endocrine data related to breast proliferation (assessed using the Ki-67/MIB-1 monoclonal antibody) and PR levels (determined by enzyme immunoassay) in the breast cancer tissue. In the healthy women the percentage of MIB-1(+) cells showed significant negative correlations with serum levels of total T, calculated free T (fT) and the fT/E(1) ratio; while in the breast cancer patients PR content showed significant negative correlations with fT level, the fT/E(1) ratio and the T/SHBG ratio. No other correlations were found in any of the groups. Our findings in healthy women confirm previous reports of an antiproliferative effect of androgens in breast tissue and our finding in breast cancer patients suggests that this antiproliferative effect may be mediated via downregulation of PR.



___
Source: http://www.hubmed.org/display.cgi?uids=18645713
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Fraction size in radiation treatment for breast conservation in early breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Fraction size in radiation treatment for breast conservation in early breast cancer.
To: mesothelioma77@gmail.com


[1]Cochrane Database Syst Rev. 2008; CD003860
James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE

BACKGROUND: Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conservation. It may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen if the shorter treatment is as effective and safe as conventional radiation therapy. OBJECTIVES: To assess the effects of altered fraction size on women with early breast cancer who have undergone breast conserving surgery. SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register (June 2006), MEDLINE (November 2006), EMBASE (November 2006), reference lists for articles, and relevant conference proceedings. No language constraints were applied. SELECTION CRITERIA: Randomised controlled trials of unconventional versus conventional fractionation in women with early breast cancer who had undergone breast conserving surgery. DATA COLLECTION AND ANALYSIS: Data extraction was performed independently by the authors with disagreements resolved by discussion. Missing data was sought by contacting the authors concerned. MAIN RESULTS: Two trials were included and reported on 2644 women. The women were highly selected with node negative tumours smaller than 5 cm and negative pathological margins; 46% of the women had a cup separation size of less than 25 cm. The studies were of high quality. Data for local recurrence and breast appearance were not available in a form which could be combined. Unconventional fractionation (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not appear to affect: (1) local-recurrence free survival (absolute difference 0.4%, 95% CI -1.5% to 2.4%), (2) breast appearance (risk ratio (RR) 1.01, 95% CI 0.88 to 1.17; P = 0.86), (3) survival at five years (RR 0.97, 95% CI 0.78 to 1.19; P = 0.75), (4) late skin toxicity at five years (RR 0.99, 95% CI 0.44 to 2.22; P = 0.98, or (5) late radiation toxicity in sub-cutaneous tissue (RR 1.0, 95% CI 0.78 to 1.28; P = 0.99). AUTHORS' CONCLUSIONS: We have evidence from two high quality randomised trials that the use of unconventional fractionation regimes (greater than 2 Gy per fraction) does not affect breast appearance or toxicity and does not seem to affect local recurrence for selected women treated with breast conserving therapy. These are women with node negative tumours smaller than 5 cm and negative pathological margins. Two new trials have been published in March 2008. Their results are consistent with our findings. The results of these trials will be incorporated in the next update of this review.



___
Source: http://www.hubmed.org/display.cgi?uids=18646095
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Thu, Jul 24, 2008 at 7:30 AM
Subject: Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
To: mesothelioma77@gmail.com


[1]Climacteric. 2008 Aug; 11(4): 315-21
Jansen GH, Franke HR, Wolbers F, Brinkhuis M, Vermes I

OBJECTIVES: Fulvestrant is an estrogen receptor (ER) antagonist that binds, blocks and degrades the estrogen receptor and is currently used in adjuvant treatment in postmenopausal women with ER-positive breast cancer as an alternative for tamoxifen. As an antagonist, it may induce or aggravate climacteric symptoms. In order to alleviate these symptoms, one could consider hormone therapy. The objective of this study was to analyze the effect of fulvestrant alone or in combination with different steroids in human breast cancer cells in vitro, and to demonstrate whether these steroids will compromise the efficacy of fulvestrant in ER-positive breast cancer cells. METHODS: We performed experiments in vitro with various hormone therapy preparations (estradiol (E2), dihydrodydrogesterone (DHD) and tibolone) at a concentration of 10(-6) mol/l alone or combined with fulvestrant in different breast cancer cell lines, ER-positive and ER-negative. After an incubation of 144 h, proliferation and apoptosis were measured. The first was measured by quantification of the expression of cyclin D1 mRNA, the latter by the Nicoletti fragmentation assay. RESULTS: This in vitro study revealed clear differences in results when various hormone therapy preparations, alone or combined with fulvestrant, are added to ER-positive and ER-negative breast cancer cell lines. CONCLUSIONS: Our study demonstrated that fulvestrant, an ER antagonist used in the treatment of ER-positive breast cancer, combined with E2 and DHD or in combination with tibolone, is not compromised in its efficacy in inducing apoptosis in ER-positive breast cancer cell lines in vitro.



___
Source: http://www.hubmed.org/display.cgi?uids=18645697
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort?

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Do both heterocyclic amines and omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in postmenopausal women of the Malmö diet and cancer cohort?
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jul 17;
Sonestedt E, Ericson U, Gullberg B, Skog K, Olsson H, Wirfält E

Heterocyclic amines (HAs), formed when meat and fish are cooked at high temperatures, have been linked to mammary gland cancer in rats, and some epidemiological studies indicate increased breast cancer risk by consumption of well-done meat. The epidemiological evidence linking HAs per se to breast cancer is however sparse, especially from prospective studies. Moreover, high-fat diets rich in omega-6 polyunsaturated fatty acids (PUFAs) have produced higher frequencies of HA-induced mammary gland tumors in rats compared to those fed low-fat diets. The aim was to evaluate prospectively if intake of HAs is associated with breast cancer incidence, and if the association is independent of omega-6 PUFA intakes. Among women 50 years or older at baseline from the population-based prospective Malmö Diet and Cancer cohort (n = 11,699), 430 women were diagnosed with incident invasive breast cancer during a mean follow-up of 10.4 years. Information on dietary habits was collected by a modified diet history method. Cox proportional hazards regression estimated hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer associated with energy-adjusted intakes of HAs and omega-6 PUFA. Intakes of HAs were not associated with breast cancer incidence (HR, 0.94; 95% CI, 0.69-1.28, for highest compared to lowest quintile). In individuals with low HA intakes, a significant increased risk was observed among those with high intakes of omega-6 PUFAs. In conclusion, intakes of HAs are not associated with breast cancer incidence in this Swedish cohort, but dietary patterns very high in omega-6 PUFA may promote breast cancer development. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18636564
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Molecular Imaging: Reporter Gene Imaging.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 16, 2008 at 9:21 AM
Subject: Molecular Imaging: Reporter Gene Imaging.
To: mesothelioma77@gmail.com


[1]Handb Exp Pharmacol. 2008; 185/2: 167-223
Serganova I, Mayer-Kukuck P, Huang R, Blasberg R

Non-invasive in-vivo molecular genetic imaging developed over the past decade and predominantly utilises radiotracer (PET, gamma camera, autoradiography), magnetic resonance and optical imaging technology. Molecular genetic imaging has its roots in both molecular biology and cell biology. The convergence of these disciplines and imaging modalities has provided the opportunity to address new research questions, including oncogenesis, tumour maintenance and progression, as well as responses to molecular-targeted therapy. Three different imaging strategies are described: (1) "bio-marker" or "surrogate" imaging; (2) "direct" imaging of specific molecules and pathway activity; (3) "indirect" reporter gene imaging. Examples of each imaging strategy are presented and discussed. Several applications of PET- and optical-based reporter imaging are demonstrated, including signal transduction pathway monitoring, oncogenesis in genetic mouse models, endogenous molecular genetic/biological processes and the response to therapy in animal models of human disease. Molecular imaging studies will compliment established ex-vivo molecular-biological assays that require tissue sampling by providing a spatial and a temporal dimension to our understanding of disease development and progression, as well as response to treatment. Although molecular imaging studies are currently being performed primarily in experimental animals, we optimistically expect they will be translated to human subjects with cancer and other diseases in the near future.



___
Source: http://www.hubmed.org/display.cgi?uids=18626603
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Recent developments in vulvovaginal pathology.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Recent developments in vulvovaginal pathology.
To: mesothelioma77@gmail.com


[1]Histopathology. 2008 Jul 11;
McCluggage WG

This review discusses recent developments in vulvovaginal pathology. A variety of morphologically bland mesenchymal lesions occur at this site with considerable histological and immunohistochemical overlap. Aggressive angiomyxoma exhibits HMGA2 immunoreactivity in approximately 50% of cases, and this nuclear transcription factor is emerging as a useful and relatively specific marker for aggressive angiomyxoma, although occasional vulvovaginal smooth muscle neoplasms are positive. HMGA2 is useful in the diagnosis of aggressive angiomyxoma and its distinction from mimics, in the evaluation of resection margins and in the assessment of the presence or absence of residual disease in re-excisions. Aggressive angiomyxoma is almost invariably positive with oestrogen and progesterone receptors, and there have been several reports of a dramatic reduction in size following gonadotropin releasing hormone agonist therapy. Recent series of the relatively newly described entities cellular angiofibroma and superficial myofibroblastoma of the lower female genital tract have expanded upon the morphological spectrum of these neoplasms. Recently described mesenchymal lesions at this site include massive oedema and prepubertal vulval fibroma. Gastrointestinal stromal tumours have been described as primary neoplasms in the vagina, and rectovaginal septum and extragastrointestinal stromal tumour should be added to the differential diagnosis of a vulvovaginal mesenchymal lesion. Many mesenchymal lesions in the vulvovaginal region exhibit immunoreactivity with both CD34 and desmin, a somewhat unusual immunophenotype in mesenchymal lesions at other sites. It is now established that there are two distinct types of vulval intraepithelial neoplasia (VIN), most commonly termed classic and differentiated VIN, the former associated with human papillomavirus (HPV) infection. There are two corresponding types of vulval squamous carcinoma with HPV-associated and non-HPV-associated variants, the latter often arising in a vulval dystrophy and associated with p53 mutation. However, in some cases there is clinicopathological overlap between HPV-associated and non-HPV-associated squamous carcinomas, and immunohistochemistry with p16 is more reliable than morphology in predicting the presence of HPV. There have been new developments regarding Paget's disease of the vulva with the identification of markers that are useful in diagnosis and evidence that the neoplastic cells represent a proliferation of adnexal stem cells residing in sebaceous units. The newly described entity vaginal tubulo-squamous polyp typically exhibits immunopositivity with prostatic markers, possibly indicating derivation from displaced periurethral Skene's glands.



___
Source: http://www.hubmed.org/display.cgi?uids=18637148
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Terpenoids from the tuber of Cremastra appendiculata.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Terpenoids from the tuber of Cremastra appendiculata.
To: mesothelioma77@gmail.com


[1]J Asian Nat Prod Res. 2008 Jul; 10(7): 677-83
Li S, Xue Z, Wang SJ, Yang YC, Shi JG

Two new terpenoids including a cadinane sesquiterpene (1), and an ent-kaurane diterpene diglycoside (2), together with a known triterpene containing 32 carbons (3), have been isolated from the ethanolic extract of Cremastra appendiculata. Their structures were established by the spectroscopic methods including the IR, MS, 1D-, and 2D-NMR experiments as ( - )-cadin-4,10(15)-dien-11-oic acid (1), ( - )-ent-12beta-hydroxykaur-16-en-19-oic acid, 19-O-beta-d-xylopyranosyl-(1 --> 6)-O-beta-d-glucopyranoside (2), and (+)-24,24-dimethyl-25,32-cyclo-5alpha-lanosta-9(11)-en-3beta-ol (3). Compounds 1-3 were evaluated against several human cancer cell lines. Compound 3 showed in vitro-selective cytotoxicity against human breast cancer cell lines (MCF-7) with an IC(50) of 3.18 muM, but 1 and 2 were inactive (IC(50)>10 mug/ml).



___
Source: http://www.hubmed.org/display.cgi?uids=18636382
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lung Cancer Trial Targets Asbestos-Related Disease (ABC 7 El Paso)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Lung Cancer Trial Targets Asbestos-Related Disease (ABC 7 El Paso)
To: mesothelioma77@gmail.com


MONDAY, July 21 (HealthDay News) -- Patients are being recruited for a clinical trial of a new targeted radiation and chemotherapy protocol for pleural mesothelioma, a cancer of the...

Mon, 21 Jul 2008 17:48:37 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11ils81cg/*http%3A//www.kvia.com/global/story.asp?s=8708959
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Gene panel predicts lung cancer survival, study finds (EurekAlert!)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Gene panel predicts lung cancer survival, study finds (EurekAlert!)
To: mesothelioma77@gmail.com


ANN ARBOR, Mich. — Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival.

Mon, 21 Jul 2008 14:53:29 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=125dgvbkm/*http%3A//www.eurekalert.org/pub_releases/2008-07/uomh-gpp072108.php
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Gene Panel Predicts Lung Cancer Survival (Newswise)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Gene Panel Predicts Lung Cancer Survival (Newswise)
To: mesothelioma77@gmail.com


Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment.

Mon, 21 Jul 2008 16:24:34 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11pmtt7aa/*http%3A//www.newswise.com/articles/view/542778/?sc=rsmn
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Terpenoids and breast cancer chemoprevention.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Terpenoids and breast cancer chemoprevention.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jul 19;
Rabi T, Bishayee A

Cancer chemoprevention is defined as the use of natural or synthetic agents that reverse, suppress or arrest carcinogenic and/or malignant phenotype progression towards invasive cancer. Phytochemicals obtained from vegetables, fruits, spices, herbs and medicinal plants, such as terpenoids, carotenoids, flavanoids, phenolic compounds, and other groups of compounds have shown promise in suppressing experimental carcinogenesis in various organs. Recent studies have indicated that mechanisms underlying chemopreventive action may include combinations of anti-oxidant, anti-inflammatory, immune-enhancing, and anti-hormone effects. Further, modification of drug-metabolizing enzymes, and influences on cell cycling and differentiation, induction of apoptosis, and suppression of proliferation and angiogenesis that play a role in the initiation and secondary modification of neoplastic development, have also been under investigation as possible mechanisms. This review will highlight the biological effects of terpenoids as chemopreventive agents on breast epithelial carcinogenesis, and the utility of intermediate biomarkers as indicators of premalignancy. Selected breast chemoprevention trials are discussed with a focus on strategies for trial design, and clinical outcomes. Future directions in the field of chemoprevention are proposed based on recently acquired mechanistic insights into breast carcinogenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18636327
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Understanding the concept of chemotherapy-related nausea: the patient experience.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Understanding the concept of chemotherapy-related nausea: the patient experience.
To: mesothelioma77@gmail.com


[1]Eur J Cancer Care (Engl). 2008 Jul 7;
Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA

The aim of this study was to explore the experience of chemotherapy-related nausea in patients with cancer. A qualitative study was carried out with 17 patients who had experienced nausea during their chemotherapy in the UK and USA. Nausea was described as distressing and complex symptom. Patients attempted to construct an understanding of nausea using cognitive processes such as analysing their experience of nausea and related symptoms, attributing causation to nausea and comparing their experiences not only to their own expectations, but also to others' symptom experiences. A number of concurrent and associated symptoms linked with nausea were identified. Preliminary evidence emerged for nausea as part of a cluster of symptoms. Anti-emetic medication, provider-directed management strategies and self-management strategies were used by patients to minimize the effects of nausea. Self-management techniques, such as dietary strategies, were rooted in participants' understanding of nausea and their beliefs about what caused nausea, and there was little evidence of guidance from professionals beyond advice about medication management. This study reveals some of the complexities behind chemotherapy-induced nausea, including a potential symptom cluster, and contributes towards a clearer understanding of this symptom and its effects on patients' lives.



___
Source: http://www.hubmed.org/display.cgi?uids=18637116
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Staged or simultaneous resection of synchronous liver metastases from colorectal cancer - A systematic review.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Staged or simultaneous resection of synchronous liver metastases from colorectal cancer - A systematic review.
To: mesothelioma77@gmail.com


[1]Colorectal Dis. 2008 Jul 11;
Hillingsø JG, Wille-Jørgensen P

Aim A systematic review of the literature was undertaken to estimate the differences in length of hospital stay, morbidity, mortality and long-term survival between staged and simultaneous resection of synchronous liver metastases in order to determine the level of evidence for recommendations of a treatment strategy. Methods A Pub-med search was undertaken for studies comparing patients with synchronous liver metastases, who either had a combined or staged resection of metastases. Twenty-six were considered and 16 were included based on Newcastle Ottawa Quality Assessment Scale. All studies were retrospective and had a general bias, because the staged procedure was significantly more often undertaken in patients with left-sided primary tumours and larger, more numerous and bi-lobar metastases. Analyses of primary outcomes were performed using the random effects model. Results Due to the heterogeneity of the observational studies no odds ratios were calculated. In eleven studies there were a tendency towards a shorter hospital stay in the synchronous resection group. Fourteen studies compared total perioperative morbidity and lower morbidity was observed in favour of a combined resection. Fifteen studies compared perioperative mortality, which seemed to be lower with the staged approach. Eleven studies compared five-year survival, which seemed to be similar in the two groups. Conclusion No randomized controlled trials were identified, so a meta-analysis was not performed. The evidence level is II to III with grade C recommendations. Synchronous resections can be undertaken in selected patients, provided that surgeons specialised in colorectal and hepatobiliary surgery are available.



___
Source: http://www.hubmed.org/display.cgi?uids=18637099
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: High Unmet Need Spurs European Lung Cancer Therapeutics Market (Centre Daily Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: High Unmet Need Spurs European Lung Cancer Therapeutics Market (Centre Daily Times)
To: mesothelioma77@gmail.com


Revenues in the European lung cancer therapeutics market are set to grow at an accelerated pace due to the anticipated launch of products currently in phase III of development and the recent introduction of targeted therapies. Pharmaceutical and biotech companies are investing significant amounts of money in R&D in this sector.

Mon, 21 Jul 2008 18:15:47 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11p9ng07o/*http%3A//www.centredaily.com/business/story/725197.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Gene panel predicts lung cancer survival, study finds (PhysOrg)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Gene panel predicts lung cancer survival, study finds (PhysOrg)
To: mesothelioma77@gmail.com


Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in Nature Medicine.

Mon, 21 Jul 2008 16:19:02 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11d34eiku/*http%3A//www.physorg.com/news135860184.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.
To: mesothelioma77@gmail.com


[1]Oncol Rep. 2008 Aug; 20(2): 301-8
Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Patel R, Kämmerer U, Vordermark D, Roosen K, Vince GH

Patients with autosomal recessive primary microcephaly have a small but architecturally normal brain containing a reduced number of neurons. Microcephalin and ASPM are two of the genes causing this disease. Both are centrosomal proteins involved in cell cycle regulation. Whereas microcephalin is a component of the DNA damage response and a repressor of telomerase function, ASPM is required for the proper formation of a central mitotic spindle and ensures symmetric, proliferative divisions of neuro-epithelial cells. Both proteins are also involved in the regulation of tumor growth. Microcephalin expression is reduced in breast cancer cell lines and human tumors of the ovary and prostate. Reduction in microcephalin mRNA expression correlates with increased chromosomal instability. ASPM mRNA is overexpressed in transformed human cell lines and tumors, and its increased expression is positively associated with proliferation of glioblastoma cells. Glioblastomas are the most prevalent malignant brain tumors in adults, characterized by increased invasiveness, an aggressive local growth pattern and short survival periods of patients. In this study, we analysed the expression of microcephalin mRNA and ASPM mRNA and protein in a panel of 15 glioblastomas and 15 astrocytoma WHO grade II by semi-quantitative RT-PCR, Western blotting and immunohistochemistry. Whereas microcephalin expression did not seem to be altered during glioma development, there was a clear increase in ASPM mRNA and protein expression that corresponded with the WHO grade of the tumor. Our findings are significant as the expression of ASPM may be used as a marker for glioma malignancy and represents a potential therapeutic target.



___
Source: http://www.hubmed.org/display.cgi?uids=18636190
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bilateral breast carcinoma - Risk factors and outcomes for patients with synchronous and metachronous disease

---------- Forwarded message ----------
From: Connotea: Bookmarks matching tags breast and cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Bilateral breast carcinoma - Risk factors and outcomes for patients with synchronous and metachronous disease
To: mesothelioma77@gmail.com


[1]

[2]Bilateral breast carcinoma - Risk factors and outcomes for patients with synchronous and metachronous disease

Bilateral breast carcinoma

Dwight Heron et al.

Cancer 88 (12), 2739-50 (2000)

info:pmid/10870056 | info:doi/10.1002/1097-0142(20000615)88:12%3C2739::AID-CNCR12%3E3.0.CO;2-J

Posted by [3]mjpires to [4]synchonous [5]metachronous [6]breast [7]risk factors [8]cancer on [9]Thu Jul 17 2008 at 18:56 UTC | [10]info | related

mjpires

___
Source: http://www.connotea.org/user/mjpires/uri/eaaad6be066e910c48f069205341d2c6
--
 ~
Powered by [14]RssFwd, a service of [15]Blue Sky Factory, Inc

 

Fwd: Expression of Indian Hedgehog signaling molecules in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Expression of Indian Hedgehog signaling molecules in breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jul 18;
Xuan Y, Lin Z

PURPOSE: To investigate the clinicopathological significance and expression pattern of Hedgehog (Hh) signaling molecules in breast normal glands and invasive ductal carcinoma. MATERIALS AND METHODS: A total of 142 cases, including 21 of normal breast and 121 of invasive ductal carcinoma of the breast, were immunohistochemically analyzed for Ihh, Ptch, Smo, Gli-1, Gli-2, and Gli-3 protein expression. RESULTS: All of Hh signaling molecules were greatly enhanced in invasive ductal carcinoma compared with the normal breast epithelia. The expressions of Ihh, Smo, and Gli-2 were increased in PR negative cases, and the expressions of Ihh, Ptch, and Gli-1/2/3 were statistically correlated with increased proliferating index of Ki-67 in invasive ductal carcinoma. Ihh and Gli-1/2/3 expressions were correlated with node metastasis. Additionally, the protein expressions of Ihh, Ptch, and Gli-2 were correlated with the clinical stage of breast cancer. CONCLUSIONS: Hedgehog signaling molecules play an important role in the progression of invasive ductal carcinoma of breast.



___
Source: http://www.hubmed.org/display.cgi?uids=18636275
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Strict sun protection results in minimal skin changes in a patient with xeroderma pigmentosum and a novel c.2009delG mutation in XPD (ERCC2).

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Strict sun protection results in minimal skin changes in a patient with xeroderma pigmentosum and a novel c.2009delG mutation in XPD (ERCC2).
To: mesothelioma77@gmail.com


[1]Exp Dermatol. 2008 Jul 7;
Emmert S, Ueda T, Zumsteg U, Weber P, Khan SG, Oh KS, Boyle J, Laspe P, Zachmann K, Boeckmann L, Kuschal C, Bircher A, Kraemer KH

We examined the clinical, molecular and genetic features of a 16-year-old boy (XP2GO) with xeroderma pigmentosum (XP) and progressive neurological symptoms. The parents are not consanguineous. Increased sun sensitivity led to the diagnosis of XP at 2 years of age and a strict UV protection scheme was implemented. Besides recurrent conjunctivitis and bilateral pterygium, only mild freckling was present on his lips. He shows absent deep tendon reflexes, progressive sensorineural deafness and progressive mental retardation. MRI shows diffuse frontal cerebral atrophy and dilated ventricles. Symptoms of trichothiodystrophy (brittle hair with a tiger-tail banding pattern on polarized microscopy) or Cockayne syndrome (cachectic dwarfism, cataracts, pigmentary retinopathy and spasticity) were absent. XP2GO fibroblasts showed reduced post-UV cell survival (D(37) = 3.8 J/m(2)), reduced nucleotide excision repair, reduced expression of XPD mRNA and an undetectable level of XPD protein. Mutational analysis of the XPD gene in XP2GO revealed two different mutations: a common p.Arg683Trp amino acid change (c.2047C>T) known to be associated with XP and a novel frameshift mutation c.2009delG (p.Gly670Alafs*39). The latter mutation potentially behaves as a null allele. While not preventing neurological degeneration, early diagnosis and rigorous sun protection can result in minimal skin disease without cancer in XP patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18637129
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Cancer genomics and genetics of FGFR2 (Review).

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Cancer genomics and genetics of FGFR2 (Review).
To: mesothelioma77@gmail.com


[1]Int J Oncol. 2008 Aug; 33(2): 233-7
Katoh M

FGFR2 gene encodes FGFR2b in epithelial cells, and FGFR2c in mesenchymal cells. FGFR2b is a high affinity receptor for FGF1, FGF3, FGF7, FGF10 and FGF22, while FGFR2c for FGF1, FGF2, FGF4, FGF6, FGF9, FGF16 and FGF20. Here genomics and genetics of FGFR2, and therapeutics targeted to FGFR2 will be reviewed. Single nucleotide polymorphisms (SNPs) of FGFR2 are associated with increased risk of breast cancer. Gene amplification or missense mutation of FGFR2 occurs in gastric cancer, lung cancer, breast cancer, ovarian cancer, and endometrial cancer. Genetic alterations of FGFR2 induce aberrant FGFR2 signaling activation due to release of FGFR2 from autoinhibition, or creation of FGF signaling autocrine loop. Class switch of FGFR2b to FGFR2c is associated with more malignant phenotype. FGF and canonical WNT signals synergize during mammary carcinogenesis, but counteract during osteogenesis and adipogenesis. Among PD173074, SU5402, and AZD2171 functioning as FGFR inhibitors, AZD2171 is the most promising anti-cancer drug. Cancer genomics and genetics are utilized to predict cancer-driving pathway for therapeutic optimization. FGFR2ome is defined as a complete data set of SNP, copy number variation (CNV), missense mutation, gene amplification, and predominant isoform of FGFR2. FGFR2ome analyses in patients with several tumor types among various populations should be carried out to establish integrative database of FGFR2 for the rational clinical application of FGFR2-targeted cancer therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18636142
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Comparison of chromogenic in situ hybridisation with fluorescence in situ hybridisation and immunohistochemistry for the assessment of her-2/neu oncogene in archival material of breast carcinoma.
To: mesothelioma77@gmail.com


[1]Acta Histochem Cytochem. 2008 Jun 27; 41(3): 59-64
Pothos A, Plastira K, Plastiras A, Vlachodimitropoulos D, Goutas N, Angelopoulou R

The successful treatment of breast cancer is dependent upon a number of complex factors. Her-2/neu gene amplification is known to be one of the most common genetic alterations associated with breast cancer and its accurate determination has become necessary for the selection of patients for trastuzumab therapy.The aim of this study was to prove the consistency of chromogenic in situ hybridisation (CISH) technique after analyzing the overexpression of the Her-2/neu proto-oncogene in 100 invasive breast carcinomas and by comparing CISH results with immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). Moreover, it was done to evaluate the possible correlation of estrogen (ERs) and progesterone receptors (PRs), the proliferation marker Ki67 and the tumour suppressor gene p53 with HER-2/neu status of these breast carcinomas.Of the 100 breast carcinomas that were analysed, 22 cases showed HER-2/neu amplification, 66 cases showed no amplification, whereas 12 cases were non-interpretable in both assays (FISH and CISH). Consequently, the overall concordance between FISH and CISH was 100%. Additionally, it was observed that when HER-2/neu gene was overexpressed, there was an association with negative PRs and ERs status, negative p53 protein expression and high Ki67 labelling index.It is concluded that patients with tumours scoring 2+ with the CBE356 antibody (borderline immunohistochemistry-tested cases) would also benefit from CISH as it is shown to be highly accurate, practical and can be easily integrated into routine testing in any histopathology laboratory. Finally, CISH represents an important addition to the HER2 testing algorithm.



___
Source: http://www.hubmed.org/display.cgi?uids=18636112
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lymphomas Involving the Breast: A Study of 106 Cases Comparing Localized and Disseminated Neoplasms.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Lymphomas Involving the Breast: A Study of 106 Cases Comparing Localized and Disseminated Neoplasms.
To: mesothelioma77@gmail.com


[1]Am J Surg Pathol. 2008 Jul 16;
Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ

Lymphomas involving the breast account for approximately 2% of extranodal and

___
Source: http://www.hubmed.org/display.cgi?uids=18636016
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Influence of hospital and surgeon volumes on operative time, blood loss and perioperative complications in radical nephrectomy.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Influence of hospital and surgeon volumes on operative time, blood loss and perioperative complications in radical nephrectomy.
To: mesothelioma77@gmail.com


[1]Int J Urol. 2008 Jul 10;
Yasunaga H, Yanaihara H, Fuji K, Matsuyama Y, Deguchi N, Ohe K

Objectives: We conducted a nationwide multi-center survey using medical record-based data to investigate the relationship between hospital/surgeon volumes and various outcomes, including operative time, volume of blood loss, and incidence of perioperative complications, in radical nephrectomy for renal cell carcinoma. Methods: We investigated a total of 1704 patients who underwent radical nephrectomy at 461 hospitals in Japan between November 2006 and February 2007. The association between hospital/surgeon volumes and operative time, volume of blood loss, and incidence of perioperative complications were independently analyzed using multivariate regression analysis against age, gender, operation site, cancer stage, serum creatinine levels, comorbid conditions, and surgical technique (open surgery or minimally invasive surgery). Results: Neither hospital volume nor surgeon volume was a significant predictor of operative time or volume of blood loss. We did not identify any association between hospital volume and perioperative complications. High-volume (> 100) surgeons were unlikely to have perioperative complications compared to low-volume (

___
Source: http://www.hubmed.org/display.cgi?uids=18637158
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Risk prediction models with incomplete data with application to prediction of estrogen receptor positive breast cancer: prospective data from the Nurses' Health Study

---------- Forwarded message ----------
From: Connotea: Bookmarks matching tags breast and cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Risk prediction models with incomplete data with application to prediction of estrogen receptor positive breast cancer: prospective data from the Nurses' Health Study
To: mesothelioma77@gmail.com


[1]

[2]Risk prediction models with incomplete data with application to prediction of estrogen receptor positive breast cancer: prospective data from the Nurses' Health Study

Bernard Rosner et al.

Breast Cancer Research 10 (4), R55 (03 Jul 2008)

info:doi/10.1186/bcr2110

Posted by [3]jls1948 to [4]estradiol [5]breast [6]prediction [7]Markers [8]cancer on [9]Wed Jul 16 2008 at 14:40 UTC | [10]info | related

jls1948

___
Source: http://www.connotea.org/user/jls1948/uri/6d435688f689048c3352733103d720fe
--
 ~
Powered by [14]RssFwd, a service of [15]Blue Sky Factory, Inc

 

Fwd: Bilateral synchronous breast cancer in a male.

---------- Forwarded message ----------
From: Connotea: Bookmarks matching tags breast and cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Bilateral synchronous breast cancer in a male.
To: mesothelioma77@gmail.com


[1]

[2]Bilateral synchronous breast cancer in a male.

Peter B Kahla et al.

The Mount Sinai journal of medicine, New York 72 (2), 120-3 (Mar 2005)

info:pmid/15770342

Posted by [3]mjpires to [4]synchonous [5]sentinel lymph node [6]bilateral [7]breast [8]Male [9]cancer on [10]Thu Jul 17 2008 at 18:52 UTC | [11]info | related

mjpires

___
Source: http://www.connotea.org/user/mjpires/uri/95bccd3159b3bced492875d02ab92a48
--
 Powered by [15]RssFwd, a service of [16]Blue Sky Factory, Inc

 

Fwd: The use of complementary therapy by men with prostate cancer in the UK.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: The use of complementary therapy by men with prostate cancer in the UK.
To: mesothelioma77@gmail.com


[1]Eur J Cancer Care (Engl). 2008 Jul 7;
Wilkinson S, Farrelly S, Low J, Chakraborty A, Williams R, Wilkinson S

The study aims were to determine the use of complementary therapies (CT) by men with prostate cancer, and to explore factors influencing CT use and attitudes toward CT use. A cross-sectional survey design was used in which a postal questionnaire was mailed to an eligible sample of 405 patients with prostate cancer receiving outpatient treatment in a London teaching hospital. The primary outcomes were the prevalence of CT use and the relationship between CT use and mental health status. Two hundred and ninety-four patients (73%) responded, of whom 25% were using CT. The most frequently used CTs were vitamins, low-fat diets, lycopene and green tea. Multivariate analyses revealed no differences in mental health scores between CT users and non-users. CT users were younger (OR 0.93, 95% CI 0.89-0.97) and were more likely to be receiving conservative management in the form of 'active surveillance' (OR 5.23, 95% CI 1.78-15.41) compared with non-users. Over half of the participants (55%) wanted to learn more about CT. Forty-three per cent of CT users had not informed any doctor about their CT use. Clinicians need to be aware of the prevalence of CT use amongst patients with prostate cancer, considering the potential harm that could be caused by interactions with conventional treatments.



___
Source: http://www.hubmed.org/display.cgi?uids=18637112
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Mechanism for gastric cancer development by Helicobacter pylori infection.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Mechanism for gastric cancer development by Helicobacter pylori infection.
To: mesothelioma77@gmail.com


[1]J Gastroenterol Hepatol. 2008 Jun 10;
Chiba T, Marusawa H, Seno H, Watanabe N

Helicobacter pylori (H. pylori) infection plays a crucial role in the development of gastric cancer. There are two major pathways for the development of gastric cancer by H. pylori infection: the indirect action of H. pylori on gastric epithelial cells through inflammation, and the direct action of the bacteria on epithelial cells through the induction of protein modulation and gene mutation. Both pathways work together to promote gastric carcinogenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18637055
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Canadian academics call for asbestos report to be published.

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Canadian academics call for asbestos report to be published.
To: mesothelioma77@gmail.com


[1]BMJ. 2008 Jun 7; 336(7656): 1269
Spurgeon D





___
Source: http://www.hubmed.org/display.cgi?uids=18535052
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Risk of Development of Lung Cancer Is Increased in Patients with Rheumatoid Arthritis: A Large Case Control Study in US Veterans.

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Risk of Development of Lung Cancer Is Increased in Patients with Rheumatoid Arthritis: A Large Case Control Study in US Veterans.
To: mesothelioma77@gmail.com


[1]J Rheumatol. 2008 Jul 15;
Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM

OBJECTIVE: To investigate the occurrence of lung cancer in patients with rheumatoid arthritis (RA) in the US veteran population. Patients with rheumatic diseases appear to have an increased risk for the development of lymphoproliferative and some solid organ malignancies. METHODS: We conducted a retrospective case control study using prospectively collected data from the Veterans Integrated Service Networks (VISN) 16 Veteran Affairs (VA) database from 1998 to 2004. We studied the association of RA and lung cancer and analyzed data on 483,721 VA patients. Patients were identified by searching for the diagnoses of RA and lung cancer based on the International Classification of Diseases (ICD) codes. We identified 8768 (1.81%) patients with a diagnosis of RA (ICD code 714.0), 7280 (1.5%) patients with lung cancer (ICD code 162.0), 247 patients with lung cancer and RA, and 7033 patients with lung cancer but no RA. Logistic regression analysis was performed to adjust for age, gender, race, and tobacco and asbestos exposure. Statistical tests were conducted at a 5% level of significance. RESULTS: The diagnosis of RA was determined to have a significant association with lung cancer in this veteran population. Patients with RA are 43% (odds ratio 1.43) more likely to develop lung cancer than patients without RA, when adjusted for covariates. CONCLUSION: Our study shows a significant positive association between RA and the development of lung cancer in the veteran population. Veterans with RA have an increased incidence of lung cancer when compared to the non-RA population.



___
Source: http://www.hubmed.org/display.cgi?uids=18634160
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc